Can-Fite BioPharma Ltd.
CANF NYSE· Pharmaceutical Preparations
Last close · Oct 30, 2026
$1.62
KIRA · Stoqly’s AI analyst, in plain words
- Can-Fite BioPharma Ltd. had only $0.4M of revenue in fiscal 2025: it is still developing what it sells. It spent $6.7M on research and development, 65% of its operating costs.
- Its operating margin was −2,456.8%, down 1,250.6 pts: of every 100 in sales, about −2,457 is left after running the business.
- Can-Fite BioPharma Ltd. lost $9.8M in fiscal 2025. With no meaningful sales yet, it pays for its work from the cash it holds.
- Free cash flow was −$9.0M in fiscal 2025, −2,210.1% of revenue. At that burn of $9.0M a year, its $5.5M of cash and short-term investments would last about 0.6 years.
Market cap
$1.3M
P/E
—
Revenue
$0.4M
Net income
−$9.8M
Free cash flow
−$9.0M
Operating margin
−2,456.8%
Can-Fite BioPharma Ltd. in 30 seconds · fiscal 2025
Are shareholders being diluted?
+126.9%
A lot. The share count rose 126.9% last year, so each share owns noticeably less.
Does it make a profit?
$6.7M R&D
Not yet: it has no meaningful sales. It spent $6.7M on research and development, 65% of its operating costs.
How long would its cash last?
0.6 yrs
Not long. It burns $9.0M a year and holds $5.5M, under a year at that pace, so it may need new money soon.
How healthy are the accounts?
1 / 7
It passes 1 of 7 health tests, but most of them need sales, so the score says little before revenue starts.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Can-Fite BioPharma Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 26, 2026
- Legal name
- Can-Fite BioPharma Ltd.
- CIK
- 0001536196
Can-Fite BioPharma Ltd. · CANF · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.9M | $0.8M | $0.7M | $0.7M | $0.4M |
| Revenue growth | 11.8% | −5.0% | −8.3% | −9.3% | −39.9% |
| Net interest income | $0.2M | −$0.1M | — | — | — |
| Operating margin | −1,505.5% | −1,246.4% | −1,103.0% | −1,206.2% | −2,456.8% |
| Net income | −$12.6M | −$10.2M | −$7.6M | −$7.9M | −$9.8M |
| Net margin | −1,478.9% | −1,255.9% | −1,027.5% | −1,169.1% | −2,426.7% |
| Diluted EPS | −$0.06 | −$0.02 | −$35.84 | −$21.72 | −$11.94 |
| Cash | |||||
| Cash from operations | −$9.9M | −$10.8M | −$8.4M | −$7.6M | −$8.9M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$9.9M | −$10.8M | −$8.4M | −$7.6M | −$9.0M |
| FCF margin | −1,157.0% | −1,334.6% | −1,136.2% | −1,133.8% | −2,210.1% |
| Dividends paid | $2.6M | — | — | — | — |
| Share count change | 54.3% | 47.5% | −99.9% | 70.2% | 126.9% |
| Debt and strength | |||||
| Cash and short-term investments | $4.6M | $3.0M | $4.3M | $4.8M | $5.5M |
| Shareholders' equity | $14.4M | $4.5M | $6.2M | $5.4M | $5.6M |
| Current ratio | 7.4x | 3.7x | 4.9x | 4.4x | 3.5x |
| Interest coverage | — | — | −16.2x | −27.9x | −35.0x |
| Returns and quality | |||||
| Return on equity | −123.3% | −107.9% | −142.5% | −134.9% | −178.2% |
| Return on tangible equity | −87.7% | −227.5% | −122.3% | −145.0% | −175.8% |
| Piotroski F-score | 2 | 1 | 3 | 1 | 1 |
| Altman Z'' | −18.7 | −54.6 | −50.3 | −58.9 | −61.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Can-Fite BioPharma Ltd. · CANF · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.62 a share, the company is worth $1.3M.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001536196). Latest version: stoqly.net/companies/canf. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.